Oncology journal

Which Patients With Early-Stage Triple-Negative Breast Cancer Should Receive a Platinum?

William M. Sikov, MD

  H&O  What forms of cancer are typically treated with platinum agents? WS  Platinum analogues are used to treat a wide range of solid tumors, including […]

In This Issue

Immunotherapy in Urothelial Cancer, Part 2: Adjuvant, Neoadjuvant, and Adjunctive Treatment

Steven S. Yu, MD, Leslie K. Ballas, MD, Eila C. Skinner, MD, Tanya B. Dorff, MD, Sarmad Sadeghi, MD, PhD, and David I. Quinn, MBBS (Hons), PhD, FRACP, FACP

From Recent Issues

Drug Development for Rare Cancers in Children

  H&O  How is a rare cancer defined? LG  Approximately 1.6 million cases of cancer are diag­nosed each year in the United States. The US Food […]

Testicular Cancer Update

  Abstract: The advances seen in the treatment of testicular cancer are among the great achievements in modern medicine. These advances were made possible by the […]

Non–Clear Cell Renal Cell Carcinomas: Biological Insights and Therapeutic Challenges and Opportunities

  Abstract: The non–clear cell renal cell carcinomas (nccRCCs) are a diverse group of rare-variant renal carcinomas. Each subtype harbors a distinct cell of origin and […]

Supplements

Highlights in Ovarian Cancer From the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer

A Review of Selected Presentations From the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer March 12-15, 2017 • National Harbor, Maryland Special Reporting […]

Recent Advances in the Management of Gastroenteropancreatic Neuroendocrine Tumors: Insights From the 2017 ASCO Gastrointestinal Cancers Symposium

Clinical Advances in Hematology & Oncology April 2017, Volume 15, Issue 4, Supplement 4 Renuka Iyer, MD, Alexandria T. Phan, MD, and J. Philip Boudreaux, MD, FACS Abstract: […]

Perspectives in Chronic Lymphocytic Leukemia: A Post-ASH Update

Clinical Advances in Hematology & Oncology February 2017 Special Supplement Considerations in the Frontline Treatment of Chronic Lymphocytic Leukemia: A Post-ASH Update Susan M. O’Brien, MD […]